Product Information
CHILD CETIRIZINE HCL 1 MG/ML is a generic product labeled by Quagen Pharmaceuticals LLC, priced at $0.0379 per ML under NDC 70752010406. Its NADAC has been published 179 times since May 3, 2023.
FDA first approved this application on May 16, 2019.
Strength
1 mg/mL
Manufacturer
Quagen Pharmaceuticals LLCNDC
70752010406
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CETIRIZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212266FDA Approved
5/16/2019
On Market Since
10/15/2022
Pharmacological Classes
Price Statistics
The NADAC for CHILD CETIRIZINE HCL 1 MG/ML has been published 179 times since May 3, 2023, and over the history we have for it it has risen 11.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0379 per ML |
|---|---|
| All-time high | $0.0396 (Nov 13, 2024) |
| All-time low | $0.0293 (Nov 20, 2024) |
| 52-week high | $0.0379 |
| 52-week low | $0.0353 |
| Median price | $0.0354 |
| Average price | $0.0353 |
| Largest weekly change | -26.1% (Nov 20, 2024) |
| Weeks tracked | 179 |
| Tracking since | May 3, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 41% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quagen Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CETIRIZINE HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHILD CETIRIZINE HCL 1 MG/ML?
The current National Average Drug Acquisition Cost (NADAC) for CHILD CETIRIZINE HCL 1 MG/ML, manufactured by Quagen Pharmaceuticals LLC, is $0.0379 per ML (NDC 70752010406), effective Sep 30, 2026.
How has the price of CHILD CETIRIZINE HCL 1 MG/ML changed over time?
Over the history we have for it, the NADAC for CHILD CETIRIZINE HCL 1 MG/ML has risen 11.7%. It has been tracked across 179 weekly CMS publications since May 3, 2023.
What are the highest and lowest recorded NADAC prices for CHILD CETIRIZINE HCL 1 MG/ML?
Since May 3, 2023, the NADAC for CHILD CETIRIZINE HCL 1 MG/ML has ranged from a low of $0.0293 (Nov 20, 2024) to a high of $0.0396 (Nov 13, 2024), with a median of $0.0354 per ML.
Are there cheaper alternatives to CHILD CETIRIZINE HCL 1 MG/ML?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CETIRIZINE HCL 1 MG/ML SYRUP, is $0.0223 per ML — about 41% below CHILD CETIRIZINE HCL 1 MG/ML.
Who manufactures CHILD CETIRIZINE HCL 1 MG/ML?
CHILD CETIRIZINE HCL 1 MG/ML (NDC 70752010406) is labeled by Quagen Pharmaceuticals LLC, and CMS classifies it as a generic product.